<DOC>
	<DOC>NCT01455194</DOC>
	<brief_summary>The aim of the trial is to investigate asthma control with 160 to 640 mcg ciclesonide/day. Asthma control will be assessed by the Asthma Control Questionnaire (ACQ).</brief_summary>
	<brief_title>Effect of High Dose Ciclesonide on Asthma Control</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Written informed consent was provided History of persistent bronchial asthma for at least 6 months Current treatment with an Inhaled Corticosteroid (ICS) at a stable dose in the dose range of 2001000 μg Fluticasone Propionate (FP)/day or equivalent for a minimum of 12 weeks Good inhalation technique Under the current ICS pretreatment the ACQ score ranges between ≥ 0.75 and ≥ 2 Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation Concomitant severe diseases (e.g. malignant diseases during the past 5 years [other than basal or squamous cell carcinoma], hepatitis C, acquired immune deficiency syndrome [AIDS]) Diseases which are contraindications for the use of ICS (e.g. active or inactive pulmonary tuberculosis or relevant fungal, bacterial or viral infections of the lower respiratory tract demanding specific treatment) Use of systemic glucocorticosteroids within 4 weeks (injectable depot steroids 6 weeks) before entry into the baseline period, or more than 3 times during the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ciclesonide</keyword>
	<keyword>asthma</keyword>
</DOC>